HCK Knockout HEK293T Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HEK293T cell line, engineered to disrupt the HCK gene. This pooled knockout model enables the study of HCK loss-of-function effects within a heterogeneous cell population, circumventing clonal selection artifacts while providing a robust source for biochemical and cell-based assays. The CRISPR/Cas9-mediated gene disruption eliminates HCK protein expression across the bulk culture, establishing a versatile platform for elucidating Src-family kinase signaling in an epithelial kidney background.
The host HEK293T cell line is derived from human embryonic kidney epithelia, immortalized with adenovirus 5 E1A/E1B, and stably expresses the SV40 large T antigen. These cells support high-level episomal replication of plasmids bearing the SV40 origin, making them a standard model for transient protein expression and lentiviral packaging. Their robust adherent growth and amenability to genetic manipulation facilitate a wide range of functional genomics and signaling studies.
HCK encodes a Src-family non-receptor tyrosine kinase that, although primarily expressed in hematopoietic cells, can be reconstituted in non-hematopoietic models. It is activated by upstream receptors such as integrin ??IIb??3, Fc??RI, and growth factor receptors (EGFR, PDGFR, CSF-1R) as well as GPCR agonists. Activated HCK undergoes autophosphorylation and phosphorylates key effectors including PI3K/AKT, ERK1/2, STAT3, and the guanine nucleotide exchange factor VAV, which activates RAC and CDC42 to control cytoskeletal rearrangement. HCK also interacts with LYN, FYN, SYK, BTK, and the adaptor PIK3R1, and is negatively regulated by Csk and SHP-1. This positions HCK at a convergence point for immunoreceptor and integrin signaling pathways, modulating proliferation, adhesion, migration, and innate immune responses.
In the HEK293T polyclonal knockout population, HCK gene disruption eliminates its kinase activity, allowing researchers to dissect HCK-dependent signaling in an epithelial background free from compensatory hematopoietic factors. The loss of HCK impairs downstream phosphorylation cascades, facilitating the study of its specific contributions to kinase network dynamics and adapter protein interactions. The polyclonal format minimizes clonal selection artifacts and preserves population-level heterogeneity, making it well-suited for screening campaigns and comparative signaling studies.
These cells are ideal for small molecule inhibitor screening against HCK, functional investigation of Src-family kinase cross-talk, and reconstitution assays to validate direct substrates. Typical experimental workflows include Western blotting for HCK and phospho-SFKs, phospho-flow cytometry for ERK/AKT, migration and proliferation assays, co-immunoprecipitation of interacting partners, and RT-qPCR for downstream gene targets. The knockout model supports cancer biology, inflammation, and kinase inhibitor research. For more information, please contact Ascent Research.
